HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Abstract

Aim: The protective role of high-density lipoprotein (HDL) against atherosclerosis is well known. However, both structural and functional changes of the HDL particles may affect its protective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreased HDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Some changes in HDL subfraction distributions were also studied previously, but data on structural and functional changes in dyslipidemia are not complete. Therefore, the authors aimed to evaluate these qualitative and quantitative markers of HDL in dyslipidemic patients and healthy control subjects.

Methods: Anthropometric parameters, serum levels of lipoproteins and MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patients and in 32 healthy gender-matched controls. Additionally, HDL subfractions were detected by an electrophoretic method on polyacrylamide gel (Lipoprint).

Results: Significantly higher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol, triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were found in patients compared to the healthy subjects. There were no significant differences in PON1 paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratio was significantly higher in patients. There was a shift towards the smaller HDL subfractions, but only the intermediate HDL ratio was significantly lower in patients compared to controls.

Conclusion: The results highlight the importance of HDL-associated pro- and antioxidant enzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm that quantification of HDL-C level alone provides limited data regarding HDL’s cardioprotective effect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia.

Keywords

High-density lipoprotein / subfraction / paraoxonase / myeloperoxidase / dyslipidemia

References

[1] Hafiane A.High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk..BBA Clin2015;3:175-88 PMCID:PMC4661556

[2] Yusuf S,Ounpuu S,Avezum A,McQueen M,Pais P,Lisheng L.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study..Lancet2004;364:937-52

[3] Ramirez A.Low high-density lipoprotein and risk of myocardial infarction..Clin Med Insights Cardiol2015;9:113-7 PMCID:PMC4670046

[4] Annema W.Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy..Transl Res2016;173:30-57

[5] Huang Y,Levison BS,Li L,Buffa J,Gerstenecker GS,Kadiyala CS,Culley MK,Didonato AJ,Berisha SZ,Nguyen TT,Chuang CC,Plow EF,Gogonea V,Parks JS,Smith JD.An abundant dysfunctional apolipoprotein A1 in human atheroma..Nat Med2014;20:193-203 PMCID:PMC3923163

[6] Khine HW,Haley RW,Ayers CR.Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: observations from the dallas heart study..Atherosclerosis2017;263:156-62

[7] Mackness M.Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles..Gene2015;567:12-21 PMCID:PMC4458450

[8] Perła-Kaján J.Paraoxonase 1 and homocysteine metabolism..Amino Acids2012;43:1405-17

[9] Ben-David M,Filippi JJ,Silman I,Tawfik DS.Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1..J Mol Biol2012;418:181-96

[10] Gugliucci A.Paraoxonase 1 and HDL maturation..Clin Chim Acta2015;439:5-13

[11] Huang Y,Riwanto M,Levison BS,Fu X,Besler C,Zhang R,DiDonato AJ,Tang WH,Plow EF,Shih DM,Fisher EA,Landmesser U.Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex..J Clin Invest2013;123:3815-28 PMCID:PMC3754253

[12] Harangi M,Seres I,Molnár M,Derdák Z,Paragh G.Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity..Transl Res2009;153:190-8

[13] Ferretti G,Sahebkar A.Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials..Prog Lipid Res2015;60:50-73

[14] Balogh Z,Harangi M,Kakuk G.Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?.Diabetes Metab2001;27:604-10

[15] Nakou ES,Kiortsis DN,Tselepis AD,Elisaf MS.The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia..Expert Opin Pharmacother2008;9:3151-8

[16] Harangi M,Harangi J.Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment..Cardiovasc Drugs Ther2009;23:501-10

[17] Smolen A,Gan KN,La Du BN.Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase..Drug Metab Dispos1991;19:107-12

[18] Schaefer EJ,Asztalos BF.High-density lipoprotein metabolism, composition, function, and deficiency..Curr Opin Lipidol2014;25:194-9 PMCID:PMC5489068

[19] Li JJ,Li S,Zhu CG,Wu NQ,Liu G,Sun J.Large HDL subfraction but not HDL-C is closely linked with risk factors, coronary severity and outcomes in a cohort of nontreated patients with stable coronary artery disease: a prospective observational study..Medicine (Baltimore)2016;95:e2600 PMCID:PMC5291580

[20] Soran H,Durrington PN.Antioxidant properties of HDL..Front Pharmacol2015;6:222 PMCID:PMC4607861

[21] Wang M,Cui S,Cao J,Wu X.Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk..DNA Cell Biol2012;31:975-82

[22] Mackness B,Mackness M.Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease..Arch Med Sci2013;9:8-13 PMCID:PMC3598146

[23] Hernández-Díaz Y,Juárez-Rojop IE,Rodríguez-Pérez C,Rodríguez-Pérez JM.Effects of paraoxonase 1 gene polymorphisms on heart diseases: systematic review and meta-analysis of 64 case-control studies..Medicine (Baltimore)2016;95:e5298 PMCID:PMC5591151

[24] Zhou B,Chen Y,Wang Y,Dong M,Zhao M,Zheng L.Myeloperoxidase-oxidized high density lipoprotein impairs atherosclerotic plaque stability by inhibiting smooth muscle cell migration..Lipids Health Dis2017;16:3 PMCID:PMC5223295

[25] Teng N,Talib J,Lau AK.The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture..Redox Rep2017;22:51-73

[26] Baldus S,Meinertz T,Eiserich JP,Simoons ML.Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes..Circulation2003;108:1440-5

[27] Brennan ML,Van Lente F,Shishehbor MH,Goormastic M,McErlean ES,Nissen SE.Prognostic value of myeloperoxidase in patients with chest pain..N Engl J Med2003;349:1595-604

[28] Szentpéteri A,Varga VE,Katkó M,Fülöp P,Harangi M.Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia..Vasa2017;46:370-6

[29] Zsíros N,Lőrincz H,Katkó M,Varga VE,Paragh G.Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications..Clin Biochem2016;49:862-7

[30] Haraguchi Y,Hasokawa M,Honjo T,Mori K,Shinohara M,Ishida T.Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease..Atherosclerosis2014;234:288-94